

AMENDMENTS TO THE CLAIMS:


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-8. (Canceled)


Claim 9. (Currently Amended) A method for treating a disease and/or condition associated with the excessive release of glutamate selected from the group consisting of epileptic seizures, acute neurodegenerative diseases, chronic neurodegenerative diseases, drug-induced neurotoxicity, pain, hormonal balance disorders, thermoregulation disorders, respiration disorders, learning disorders, pattern recognition disorders, memory disorders, and disorders subsequent to hypoxia or hypoglycaemia in a patient comprising administration to said patient of a composition containing a therapeutically effective amount of at least one beta-naphthoquinone derivative and a pharmaceutically acceptable carrier, wherein said beta-naphthoquinone derivative is selected among the group consisting of:

- (i) compounds having the formula (I):



wherein R represents -NH-CO-NH₂, -NH-CO-CH₃, or -OH group,

- (ii) glucuronide derivatives thereof having the formula (II):



wherein R is as indicated in (i), and

(iii) addition salts thereof.

Claim 10. (Previously Presented). The method of claim 9, wherein said beta-naphthoquinone derivative is selected among the group consisting of the 1,2-naphthoquinone, 2-semicarbazone and the 1-(1-hydroxy,2-naphthyl)semicarbazide-1- β -O-glucopyranosiduronic acid.

Claim 11. (Canceled).

Claim 12. (Currently Amended) The method of claim ~~11~~ 9, wherein said disease and/or condition is an acute or chronic neurodegenerative ~~diseases are~~ disease selected from the group consisting of Alzheimer's disease, Huntington's disease, Parkinson's disease, multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), retinopathy, stroke, and traumatic brain injury.